Greyparrot secures $27M Series B to scale AI waste intelligence for the circular economy

Qureight, a leading end-to-end imaging company specializing in clinical trials for lung and heart disease, has secured $20 million in Series B funding to expand its AI-powered imaging platform. The investment round, led by Molten Ventures, also saw participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension. This brings Qureight's total funding to over €27 million.

The company's platform offers a range of innovative services, including global imaging CRO services to streamline image handling in clinical trials, proprietary AI Lung image biomarkers to quantify structural changes indicative of disease progression, and data science products such as synthetic control arms. These features aim to reduce study costs and duration.

With these funds, Qureight plans to launch new products in high-demand disease areas, including asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. These new disease models will complement the company's existing lung fibrosis models, expanding its market reach and solidifying its position as a market leader in lung and heart imaging CRO services.

Qureight's services are already being utilized by biopharma partners to provide real-time insights and precision endpoints, accelerating clinical trials in fibrotic lung diseases. Speaking about the new funding, Dr Muhunthan Thillai, Co-founder and CEO of Qureight, expressed excitement about bringing on Molten Ventures as lead investor and welcoming Dr Inga Deakin and Anna Salim to the Board of Directors. He also highlighted the company's commitment to developing advanced imaging analytics to improve clinical trial design.

Molten Ventures' Dr Inga Deakin emphasized Qureight's potential to transform clinical research through AI-powered discovery, underscoring the team's capability to address unmet medical needs and drive medical innovation.